After decades of patent protection, the wildly successful arthritis and autoimmune drug Humira is finally facing competition. WSJ’s Jared Hopkins on what that could mean for patients and the drug industry.
Further Reading:
- Blockbuster Arthritis Drug Humira Faces Competition From First Lower-Price Copycat in U.S.
- AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
Further Listening:
- How Big Pharma Lost Its Swagger
Where to Listen
